Skip to content
ABOUT
AUTHOR GUIDELINES
AUTHORS/EDITORS
SUBSCRIPTIONS
CONTACT US
MY ACCOUNT
Facebook
X
LinkedIn
Instagram
Search
×
HOME
PSYCH. BULLETIN
LATEST ISSUE
BLACK BOOK OF DOSING & MONITORING
RATING SCALES
LICENSING INFORMATION
RESOURCES
PSYCHOTROPICS A-Z
PSYCHOPHARMACOLOGY 101
NEWS
OPEN ACCESS: Serotonergic Drugs for the Treatment of Attention-Deficit/Hyperactivity Disorder: A Review of Past Development, Pitfalls and Failures, and a Look to the Future
1
x
$
0.00
Coping With Somatic Comorbidities: Striving for Complete Recovery
1
x
$
30.00
Functional Assessment Staging (FAST)
1
x
$
0.00
Paliperidone Double-blind, Placebo- and Active-Controlled, Study
1
x
$
30.00
Psychopharmacology Bulletin VOL 37 Supplement No. 2 - Full Issue Stacked PDF
1
x
$
60.00
Oncology Spectrums: Volume 2 No. 9
1
x
$
0.00
Relationship of the 1846G > A Polymorphism of the CYP2D6 Gene to the Equilibrium Concentration Levels of Haloperidol in Patients with Acute Alcoholic Hallucinosis
1
x
$
30.00
Consequences of 1,4-Butanediol Misuse: A Review
1
x
$
30.00
Influence of Plasma Concentration of Hsa-Mir-370-3p and Cyp2d6*4 On Equilibrium Concentration of Phenazepam in Patients with Recurrent Depressive Disorder
1
x
$
30.00
Sumeet Roy, PhD, MBA: Efficacy of Print Advertising for a Bipolar Disorder Study
1
x
$
30.00
Vicki L. Ellingrod, PharmD, BCPP: 5-HT2A Receptor Promoter Polymorphism, -1438G/A and Negative Symptom Response to Olanzapine in Schizophrenia
1
x
$
30.00
View Cart
Checkout
Home
serotonin
“Vicki L. Ellingrod, PharmD, BCPP: 5-HT2A Receptor Promoter Polymorphism, -1438G/A and Negative Symptom Response to Olanzapine in Schizophrenia” has been added to your cart.
View cart
Sort by
Date
Sort by
Name
Sort by
Price
Sort by
Date
Sort by
Popularity
Show
20 Products
Show
20 Products
Show
40 Products
Show
60 Products
Neuropharmacology of Paroxetine
$
30.00
Add to cart
Details
New Goals in the Treatment of Depression: Moving Toward Recovery By Michael E. Thase, MD, and Philip T. Ninan, MD
$
30.00
Add to cart
Details
Long-Term Treatment Strategies in Affective Disorders
$
30.00
Add to cart
Details
Long-Term Treatment Strategies in Anxiety Disorders
$
30.00
Add to cart
Details
Optimizing Treatment Outcomes for Patients With Depression and Generalized Anxiety Disorder
$
30.00
Add to cart
Details
Coping With Somatic Comorbidities: Striving for Complete Recovery
$
30.00
Add to cart
Details
Depression Treatment: A Lifelong Commitment?
$
30.00
Add to cart
Details
Unraveling the Diagnostic Clues of Depression and GAD: The Primary Care Challenge
$
30.00
Add to cart
Details
Can We Distinguish Anxiety From Depression?
$
30.00
Add to cart
Details
Neuropharmacology of Paroxetine
$
30.00
Add to cart
Details
In Vivo Neuroimaging Correlates of the Efficacy of Paroxetine in the Treatment of Mood and Anxiety Disorders
$
30.00
Add to cart
Details
Alexander Neumeister, MD: Tryptophan Depletion, Serotonin, and Depression: Where Do We Stand?
$
30.00
Add to cart
Details
Gregory M. Asnis, MD: IFN-Induced Depression: A Role for NSAIDs
$
30.00
Add to cart
Details
Paolo Castrogiovanni, MD: Can Serotonin and Fluoxetine Levels in Plasma and Platelets Predict Clinical Response in Depression?
$
30.00
Add to cart
Details
Vicki L. Ellingrod, PharmD, BCPP: 5-HT2A Receptor Promoter Polymorphism, -1438G/A and Negative Symptom Response to Olanzapine in Schizophrenia
$
30.00
Add to cart
Details
Elliott Richelson, MD: The Clinical Relevance of Antidepressant Interaction With Neurotransmitter Transporters and Receptors
$
30.00
Add to cart
Details
Jay D. Kranzler, MD, PhD: The Psychopharmacology of Fibromyalgia: A Drug Development Perspective
$
30.00
Add to cart
Details
Tyler M. McLeod, BS: Nitric Oxide, Stress, and Depression
$
30.00
Add to cart
Details
Duloxetine in Military Posttraumatic Stress Disorder
$
30.00
Add to cart
Details
Indira Varia, MD: Effect of Mirtazapine Orally Disintegrating Tablets on Health-Related Quality of Life in Elderly Depressed Patients with Comorbid Medical Disorders: A Pilot Study
$
30.00
Add to cart
Details
1
2
Next
Page load link
Go to Top
